11.05.2020 • NewsBachemDede Willams

Bachem and Jitsubo in Licensing Agreement

Swiss CDMO Bachem has signed an exclusive licensing agreement to use the liquid phase peptide manufacturing technology Molecular Hiving developed by Japan’s Jitsubo.

Bachem and Jitsubo in Licensing Agreement (c) Bachem
Bachem and Jitsubo in Licensing Agreement (c) Bachem

The latest agreement, which builds on previous collaborations between the two companies, covering active pharmaceutical ingredients (APIs) and cosmetic peptides, calls for Jitsubo to develop selected manufacturing processes for Bachem.

The Swiss company with subsidiaries in the US, UK and Japan will further optimize, scale up and produce for commercial applications, and Jitsubo will receive development fees and royalties.

Bachem said it expects the implementation of Molecular Hiving to result in reduced manufacturing costs, improved sustainability, greener chemistry, efficient scale up and enhanced in-process controls.

Günther Loidl, chief technology officer of Bachem Holding, said Jitsubo’s technology complements his company’s s own extensive technology base and offers “unique capabilities in the area of solid phase, hybrid, and solution phase peptide chemistry.”

Jitsubo CEO Kazuaki Kanai said the licensing agreement, which will provide opportunities to deliver products to customers much faster and at greater scale.

Company

Logo:

Bachem

Hauptstr. 144
4416 Bubendorf
Switzerland

Company contact







Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Interview

Fostering Innovation and Collaboration
Specialty Chemicals Distributor IMCD’s Strategy

Fostering Innovation and Collaboration

Valerie Diele-Braun, CEO of IMCD, shares her vision for sustainability, global expansions, and strategic direction in an exclusive CHEManager International interview.

most read

Photo
27.03.2025 • News

J&J to Invest $55 Billion in US Operations

US healthcare giant Johnson & Johnson (J&J) has unveiled plans to invest over $55 billion in the US over the next four years. This significant investment marks a 25% increase compared to the previous four years, the company said.

Photo
19.03.2025 • NewsInnovation

Data-Driven Enzyme Immobilization

Inseit, based in Bern, develops biocatalysts for industrial setups using enzyme immobilization and biocomputation. Addressing biotech and sustainability challenges, Inseit was selected for Venture Leaders Biotech and won two Nucleate accelerator prizes.